Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jun 24

PMID 35743089

Authors

Antonio Vitiello

Francesco Ferrara

Affiliations

Soon will be listed here.

Abstract

The new SARS-CoV-2 coronavirus is responsible for the COVID-19 pandemic. A massive vaccination campaign, which is still ongoing, has averted most serious consequences worldwide; however, lines of research are continuing to identify the best drug therapies to treat COVID-19 infection. SARS-CoV-2 penetrates the cells of the host organism through ACE2. The ACE2 protein plays a key role in the renin-angiotensin system (RAS) and undergoes changes in expression during different stages of COVID-19 infection. It appears that an unregulated RAS is responsible for the severe lung damage that occurs in some cases of COVID-19. Pharmacologically modifying the expression of ACE2 could be an interesting line of research to follow in order to avoid the severe complications of COVID-19.

Citing Articles

S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review.

Nejat R, Torshizi M, Najafi D Vaccines (Basel). 2023; 11(2).

PMID: 36851081 PMC: 9968219. DOI: 10.3390/vaccines11020204.

MLN-4760 Induces Oxidative Stress without Blood Pressure and Behavioural Alterations in SHRs: Roles of Gene, Nitric Oxide and Hydrogen Sulfide.

Kluknavsky M, Micurova A, Cebova M, Saman E, Cacanyiova S, Bernatova I Antioxidants (Basel). 2022; 11(12).

PMID: 36552591 PMC: 9774314. DOI: 10.3390/antiox11122385.

References

Chan K, Dorosky D, Sharma P, Abbasi S, Dye J, Kranz D . Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020; 369(6508):1261-1265. PMC: 7574912. DOI: 10.1126/science.abc0870. View

Guarner J . Three Emerging Coronaviruses in Two Decades. Am J Clin Pathol. 2020; 153(4):420-421. PMC: 7109697. DOI: 10.1093/ajcp/aqaa029. View

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

Imai Y, Kuba K, Penninger J . Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci. 2007; 64(15):2006-12. PMC: 7079778. DOI: 10.1007/s00018-007-6228-6. View

Vitiello A, Ferrara F . Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020; 262:118510. PMC: 7521881. DOI: 10.1016/j.lfs.2020.118510. View

Vitiello A, Ferrara F . Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020; 190(3):1249-1250. PMC: 7673242. DOI: 10.1007/s11845-020-02440-y. View

Zhang H, Penninger J, Li Y, Zhong N, Slutsky A . Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4):586-590. PMC: 7079879. DOI: 10.1007/s00134-020-05985-9. View

Nussinov R, Tsai C . The different ways through which specificity works in orthosteric and allosteric drugs. Curr Pharm Des. 2012; 18(9):1311-6. PMC: 7458136. DOI: 10.2174/138161212799436377. View

Higuchi Y, Suzuki T, Arimori T, Ikemura N, Mihara E, Kirita Y . Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat Commun. 2021; 12(1):3802. PMC: 8217473. DOI: 10.1038/s41467-021-24013-y. View

10.

Jorgensen S, Kebriaei R, Dresser L . Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy. 2020; 40(7):659-671. PMC: 7283864. DOI: 10.1002/phar.2429. View

11.

. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4):536-544. PMC: 7095448. DOI: 10.1038/s41564-020-0695-z. View

12.

Madjunkov M, Dviri M, Librach C . A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: a Canadian perspective. J Ovarian Res. 2020; 13(1):140. PMC: 7694590. DOI: 10.1186/s13048-020-00737-1. View

13.

Vitiello A, Ferrara F . Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2020; 156:105579. PMC: 7526529. DOI: 10.1016/j.ejps.2020.105579. View

14.

Tabassum A, Iqbal M, Sultan S, Alhuthali R, Alshubaili D, Sayyam R . Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19. Mediators Inflamm. 2022; 2022:7423537. PMC: 8826266. DOI: 10.1155/2022/7423537. View

15.

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

16.

Ocaranza M, Riquelme J, Garcia L, Jalil J, Chiong M, Santos R . Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2019; 17(2):116-129. PMC: 7097090. DOI: 10.1038/s41569-019-0244-8. View

17.

Muslim S, Nasrin N, Alotaibi F, Prasad G, Singh S, Alam I . Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure. SN Compr Clin Med. 2020; 2(10):1761-1766. PMC: 7442548. DOI: 10.1007/s42399-020-00407-9. View

18.

Bilezikian J, Bikle D, Hewison M, Lazaretti-Castro M, Formenti A, Gupta A . MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. Eur J Endocrinol. 2020; 183(5):R133-R147. PMC: 9494342. DOI: 10.1530/EJE-20-0665. View

19.

Vitiello A, La Porta R, Ferrara F . Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020; . DOI: 10.1136/bmjebm-2020-111497. View

20.

Vitiello A, La Porta R, Ferrara F . Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021; 147:110486. PMC: 7788318. DOI: 10.1016/j.mehy.2021.110486. View